Nike Vaporfly 4%,
does it really help with Faster outdoor approximately 3.5-km time trial than a conventional lightweight racing shoe in recreational runners?
research showsThe grade is C. In the 30-runner outdoor analysis of a counterbalanced crossover trial, time was 793±98 seconds in Vaporfly versus 802±100 seconds in Adidas Adizero Adios, about 9 seconds or 1.1% faster (P=.001). The paper-reported effect size was only 0.09, below the conventional small-effect threshold of 0.2, and evidence comes from one small unregistered trial; this gives C with 46 points.
ads claimThe shoe genuinely contains a carbon plate and the trial genuinely found a nine-second average difference. These facts do not establish a 4% race-time gain for every runner or a confirmed long-distance benefit.
Useful facts when choosing a product
- The test shoe was Nike Vaporfly 4% and the comparator was Adidas Adizero Adios.
- Thirty runners completed the outdoor counterbalanced crossover test.
- The mean difference was nine seconds, about 1.1%, with a paper-reported effect size of 0.09.
What the research actually shows
Nielsen A, Franch J, Heyde C, de Zee M et al. studied 37 runners in the laboratory and 30 in the outdoor time trial. Shoe order was counterbalanced and each runner completed the approximately 3.5-km course in both shoes. The authors disclosed that Anders Nielsen’s PhD was partly funded by Adidas and Christian Heyde was an Adidas employee. Adidas made the control shoe, so this relationship was not directionally favorable to Nike, but the evidence was not classified as fully noncommercial. Verdict 2416 addresses a cooling vest in a hot 5-km run, a different intervention.
Why this is classified as C (46)
A statistically positive but very small direct performance effect in one 30-person unregistered crossover trial gives C with 46 points. Adidas partly funded the research and supplied an employee author, but its shoe was the control, so the plausible commercial bias direction favors the control rather than Nike.
Counterpoint. Some individuals may value nine seconds, but this study cannot identify individual responders.
Rejudgment record. Cross-check applied — We cross-checked analysis count, mean times, effect size, crossover design, and disclosed commercial relationships against the peer-reviewed record and university publication page.
| Endpoint | P | Patient-reported treatment goal - the symptom is the goal |
| Replication | R1 | Single confirmatory trial |
| Independence | I1 | Mixed funding sources |
| Effect size | E~ | Statistically positive but below the threshold |
The scoring table and the verdict agree (C).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Faster outdoor approximately 3.5-km time | C | Mean time was nine seconds faster, but effect size was 0.09. |
| A 4% time improvement for every runner | ? | The average difference was about 1.1%, and a 4% individual benefit was not tested. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Study 1 | Random-order counterbalanced crossover footwear trial | 30 | Nielsen’s PhD partly funded by Adidas; Heyde was an Adidas employee, and Adidas made the control shoe | Outdoor approximately 3.5-km completion time | 793±98 versus 802±100 seconds, P=.001, effect size 0.09 | Single small direct performance trial |
Receipt — 1 References
All 1 cited sources were verified for existence at the original page (as of 2026-08-14).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-08-14 · Corrections: none
Cite this verdict
[Chamgap] Nike Vaporfly 4% x approximately 3.5-km running time — Evidence Grade C·46. 1 cited sources checked. Source: https://chamgap.com/en/verdicts/sports/nike-vaporfly-4-percent-recreational-35k-time-trial/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.